Towards targeted epigenetic therapy of cancer

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Magic, Zvonko ^a   Supic, G ^a   Brankovic Magic, M ^b  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Cancer; DNA methylation; Epigenetic; Histone modifications

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZACITIDINE; COMPLEMENTARY RNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; ESTROGEN RECEPTOR; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; MICRORNA; PROCAINAMIDE; PROCAINE; RG 108; RNA DIRECTED DNA POLYMERASE INHIBITOR; TAMOXIFEN; TRICHOSTATIN A; TUMOR MARKER; UNCLASSIFIED DRUG; VORINOSTAT; ZEBULARINE;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CONFERENCE PAPER; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA SEQUENCE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; PROGNOSIS; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

ACETYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GENE THERAPY; HISTONES; HUMANS; METHYLATION; MICRORNAS; MUTATION; NEOPLASMS; PHARMACOGENETICS;

EID: 70350044048     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Cikota B, Tukić Lj, Tarabar O, Magić Z. Detection of t[14;18], p53 and ras gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma. J Exp Clin Cancer Res 2007; 26: 515-522. (Pubitemid 351157872)
2. Strnad M, Brajušković G, Strelić N et al. Expression of programmed cell death proteins in patients with chronic myeloid leukemia. J BUON 2008; 13: 403-408.
3. Kozomara R, Jović N, Magić Z, Branković-Magic M, Minić V. p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. J Cranio-Maxillofac Surg 2005; 33: 342-348. (Pubitemid 41283254)
4. Kandolf Sekulović L, Cikota B, Jović M et al. The role of apoptosis and cell-proliferation regulating genes in mycosis fungoides. J Dermatol Sci 2009; 55: 53-56.
5. Magic Z, Radulovic S, Brankovic-Magic M. cDNA microarrays: identification of gene signatures and their application in clinical practice. J BUON 2007; 2 (Suppl 1): S39-S44. (Pubitemid 350200860)
6. Galanis E, Russell S. Cancer gene therapy clinical trials: lessons for the future. Br J Cancer 2001; 85: 1432-1436. (Pubitemid 34001569)
7. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature 2002; 3: 415-418.
8. Herman, JG, Baylin, SB. Gene silencing in cancer in association with promoter hypermethylation. N Eng J Med 2003; 349: 2042-2054. (Pubitemid 37448928)
9. Esteller M (Ed). DNA Methylation, Epigenetics and Metastasis. Springer, Madrid, 2005.
10. Esteller M (Ed). Epigenetics in Biology and Medicine. CRC Press, Madrid, 2009.
11. Szyf M (Ed). DNA Methylation and Cancer Therapy. Kluwer, Academic/Plenum Publishers, 2005.
12. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21: 5400-5413. (Pubitemid 34983477)
13. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229. (Pubitemid 32695003)
14. Hedenfalk I, Duggan D, Chen Y et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 539-548. (Pubitemid 32167867)
15. Van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
16. Schuebel K, Chen W, Cope L et al. Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer. PLOS Genetic 2007; 1709-1709 (Pubitemid 47510263)
17. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 2001; 20: 2536-2544. (Pubitemid 32452872)
18. Miremadi A, Oestergaard M, Pharoah P, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Gen 2007; 16: 28-49.
19. Agoston AT, Argani P, Yegnasubramanian S et al. Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 2005; 280: 18302-18310. (Pubitemid 41389076)
20. Girault, I, Tozlu, S, Lidereau, R, Bieche I. Expression Analysis of DNA Methyltransferases 1, 3A, and 3B in Sporadic Breast Carcinomas. Clin Cancer Res 2003; 9: 4415-4422. (Pubitemid 37248399)
21. Liang G, Chan MF, Tomigahara Y et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 2002; 22: 480-491. (Pubitemid 34027493)
22. Rhee I, Bachman KE, Park BH et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-556. (Pubitemid 34288859)
23. Margueron R, Trojer P, Reinberg D. The key to development: interpreting the histone code? Curr Opin Gen Dev 2005; 15: 163-176.
24. Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metast 2008; 25: 183-189.
25. Kazantsev A, Thompson L. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev 2008; 7: 854-868.
26. Mahlknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000; 6: 623-644.
27. Arts J, de Schepper S, Van Emelen K. Histone deacetyiase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 2003; 10: 2343-2350. (Pubitemid 37236391)
28. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetyiase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814. (Pubitemid 28099682)
29. de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases [HDACs]: characterization of the classical HDAC family. Biochem J 2003; 370: 737-749.
30. Harms KL, Chen X. Histone Deacetyiase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity. Cancer Res 2007; 67: 3145-3152. (Pubitemid 46724851)
31. Majid S, Kikuno N, Nelles J et al. Genistein Induces the p21WAF1/CIP1 and p16INK4a Tumor Suppressor Genes in Prostate Cancer Cells by Epigenetic Mechanisms Involving Active Chromatin Modification. Cancer Res 2008; 68: 2736-2744. (Pubitemid 351556271)
32. Spannhoff A, Sippl W, Jung M. Cancer treatment of the future: Inhibitors of histone methyltransferases. Int J Biochem Cell Biol 2009; 41: 4-11.
33. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood 2006; 108: 3646-3653. (Pubitemid 44864540)
34. Negrini M, Ferracin M, Sabbioni S, Croce C. MicroRNAs in human cancer: from research to therapy. J Cell Sci 2007; 120: 1833-1840. (Pubitemid 46979774)
35. Croce CM. Oncogenes and Cancer. N Engl J Med 2008; 358: 502-511
36. Lujambio A, Ropero S, Ballestar E et al. Genetic Unmasking of an Epigenetically Silenced microRNA in Human Cancer Cells. Cancer Res 2007; 67: 1424-1429. (Pubitemid 46383366)
37. Inbal B, Cohen O, Polak-Charcon S et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390: 180-184. (Pubitemid 27507988)
38. Supic G, Kozomara R, Branković-Magić M, Jović N, Magić Z. Gene Hypermethylation in Tumor Tissue of Advanced Oral Squamous Cell Carcinoma Patients. Oral Oncol, doi: 10.1016/j.oraloncology.2009.07.007
39. Graziano F, Arduini F, Ruzzo A et al. Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer. Clin Cancer Res 2004; 10: 2784-2789. (Pubitemid 38509156)
40. Nakata S, Sugio K, Uramoto H et al. The methylation status and protein expression of CDH1, p16[INK4A], and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 2006; 106: 2190-2199.
41. Koscielny S, Dahse R, Ernst G, von Eggeling F. The prognostic relevance of p16 inactivation in head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2007; 69: 30-36. (Pubitemid 46005771)
42. Zare M, Rastgar Jazii F, Reza Alivand M, Karimi Nasseri N, Malekzadeh R, Yazdanbod M. Qualitative analysis of adenomatous polyposis coli promoter: Hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer 2009; 9: 24 doi 10.1186/1471-2407-9-24.
43. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354. (Pubitemid 30826035)
44. Zuo C, Ai L, Ratliff P et al. O6-Methylguanine-DNA Methyltransferase Gene: Epigenetic Silencing and Prognostic Value in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13: 967-975. (Pubitemid 38756707)
45. Esteller M, Gaidano G, Goodman S et al. Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase and Survival of Patients With Diffuse Large B-Cell Lymphoma. J Natl Cancer Inst 2002; 94: 26-32. (Pubitemid 34082840)
46. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of MLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10: 4420-4426. (Pubitemid 38878884)
47. Agrelo R, Cheng W, Satien F et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer Proc Natl Acad Sci USA 2006; 103: 8822-8827.
48. Toyota M, Suzuki H, Yamashita T et al. Cancer epigenomics: Implications of DNA methylation in personalized cancer therapy. Cancer Sci 2009; 100: 787-791.
49. Issa JP. DNA Methylation as a Therapeutic Target in Cancer. Clin Cancer Res 2007; 13: 1634-1637. (Pubitemid 46952927)
50. Lyko F, Brown R. DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies. J Natl Cancer Inst 2005; 97: 1498-1506.
51. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacytidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-2440. (Pubitemid 34525728)
52. Ghoshal K, Bai S. DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 2007; 43: 395-422. (Pubitemid 47234771)
53. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
54. Schrump DS, Fischette MR, Nguyen DM et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12: 5777-5785.
55. Lemaire M, Chabot G, Raynal N et al. Importance of dose-schedule of 5-aza-2′-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 2008; 8: 128-137. (Pubitemid 351715874)
56. Stewart DJ, Issa JP, Kurzrock R et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009; 15: 3881-3888.
57. Fan J, Yin WJ, Lu JS et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol 2008; 134: 883-890.
58. Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat 2009 May 21 [Epub ahead of print].
59. Chuang JC, Yoo CB, Kwan JM et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2-deoxycytidine. Mol Cancer Ther 2005; 4: 1515-1520.
60. Fang MZ, Wang Y, Ai N et al. Tea polyphenol [-]-epigallocatechin-3- gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-7570.
61. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003; 63: 4984-4989. (Pubitemid 37022635)
62. Song Y, Zhang C. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol 2009; 63: 605-613.
63. Siedlecki P, Boy RG, Musch T et al. Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 2006; 49: 678-683. (Pubitemid 43157497)
64. Brueckner B, Boy RG, Siedlecki P et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005; 65: 6305-6311. (Pubitemid 40994416)
65. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-1252. (Pubitemid 350106355)
66. Fiskus W, Ren Y, Mohapatra A et al. Hydroxamic Acid Analogue Histone Deacetyiase Inhibitors Attenuate Estrogen Receptor-A Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90. Clin Cancer Res 2007; 13: 4882-4890. (Pubitemid 47294796)
67. Hostetter CL, Licata LA, Keen JC. Timing is everything: order of administration of 5-aza 2′ deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. Cancer Lett 2009; 275: 178-184.
68. Ou JN, Torrisani J, Unterberger A et al. Histone deacetyiase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 2007; 73: 1297-1307. (Pubitemid 46452588)
69. Yang X, Phillips D, Ferguson A, Nelson G, Herman J, Davidso N. Synergistic activation of functional estrogen receptor [ER]-alpha by DNA methyltransferase and histone deacetyiase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001; 61: 7025-7029.
70. Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949. (Pubitemid 41377683)
71. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006; 29: 903-906.
72. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-1486. (Pubitemid 47076526)
73. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-6033. (Pubitemid 40994386)
74. Lu Y, Xiao J, Lin H et al. A single anti-microRNA antisense oligodeoxyribonucleotide [AMO] targeting multiple microRNAs offers an improved approach for microRNA interference. Nuc Acids Res 2009; 37: e24.